JP Morgan Chase
EVFM

JP Morgan Chase’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

JP Morgan Chase’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-250
Closed – – 7187
2022
Q2 		$0 Buy
250
+199
+390% +$328 ﹤0.01% 7214
2022
Q1 		$0 Sell
51
-8,782
-99% -$55.2K ﹤0.01% 7274
2021
Q4 		$49K Buy
8,833
+8,684
+5,828% +$73.8K ﹤0.01% 5960
2021
Q3 		$1K Sell
149
-636
-81% -$7.99K ﹤0.01% 6435
2021
Q2 		$13K Sell
785
-9,066
-92% -$172K ﹤0.01% 6011
2021
Q1 		$259K Sell
9,851
-4,270
-30% -$194K ﹤0.01% 5043
2020
Q4 		$510K Buy
14,121
+11,945
+549% +$432K ﹤0.01% 4355
2020
Q3 		$78K Buy
2,176
+621
+40% +$27K ﹤0.01% 4813
2020
Q2 		$66K Buy
1,555
+1,253
+415% +$84.5K ﹤0.01% 4730
2020
Q1 		$24K Sell
302
-7
-2% -$560 ﹤0.01% 4908
2019
Q4 		$29K Hold
309
– – ﹤0.01% 5265
2019
Q3 		$23K Sell
309
-1,337
-81% -$103K ﹤0.01% 5386
2019
Q2 		$163K Buy
+1,646
New +$128K ﹤0.01% 4744

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $653M AUM 28.36% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

JP Morgan Chase's EVFM Position: Q3 2022 in Review

JP Morgan Chase sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 250 shares.

JP Morgan Chase first reported a position in EVFM in Q2 2019 and held it in 13 quarters. The position peaked at $510K in Q4 2020. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • JP Morgan Chase reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • JP Morgan Chase sold 250 Evofem Biosciences, Inc. Common Stock shares in Q3 2022.
  • JP Morgan Chase first reported a position in Evofem Biosciences, Inc. Common Stock in Q2 2019 and held it in 13 quarters.
  • JP Morgan Chase's Evofem Biosciences, Inc. Common Stock position peaked at $510K in Q4 2020.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.